Multicenter, Open-Label, 2-Arm, Pilot Trial for Safe Reduction of Basal Insulin Dose Combined with SGLT2 Inhibitor in Type 1 Diabetes Mellitus: Study Protocol for a RISING-STAR Trial.
Yoshitaka HashimotoYoshitaka HashimotoToru TanakaGoji HasegawaMichiyo IshiiHiroshi OkadaKazuteru MitsuhashiNoriyuki KitagawaEmi UshigomeMasahiro YamazakiMichiaki FukuiPublished in: Clinical medicine insights. Endocrinology and diabetes (2021)
In this pilot study, we assumed that, given a sufficient Basal, hypoglycemia would be more frequent in patients with type 1 diabetes when combined with SGLT2 inhibitors, provided the Basal was not reduced.